Sign up to save your podcasts
Or
Share Dried Blood COVID Dx, Cryo-Shocked Tumor Cell Delivery Vehicles, Verve Halts Trial, Iambic Starts Trial, and Diagonal Therapeutics Launches
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dried Blood COVID Dx, Cryo-Shocked Tumor Cell Delivery Vehicles, Verve Halts Trial, Iambic Starts Trial, and Diagonal Therapeutics Launches
Episode 16 (April 5, 2024): This week, the GEN editors discussed deep proteome profiling of home-sampled dried blood spots to assess the effects of SARS-CoV-2 in mildly symptomatic or asymptomatic, rapid liquid nitrogen treatment for converting tumor cells into carriers for gene editing tools that target cancer in vivo, Verve Therapeutics’ pausing of a clinical trial due to a serious adverse event, Iambic Therapeutics’ advancement of its first AI-designed candidate into the clinic, and the launch of Diagonal Therapeutics to find agonist antibodies for heteromeric receptor complexes.
Featuring Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN), Jonathan Grinstein, PhD, (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM)
Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:
The State of Omics 2024 Registration
GEN Summit
COVID-19 Infections Detected in Dried Blood Spots via At-Home Proteomic Profiling
By GEN, April 2, 2024.
CRISPR-Cas9 Targets Lung Cancer Using Cryo-Shocked Tumor Cells
By GEN, March 31, 2024.
Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers
By Alex Philipidis, GEN, April 3, 2024.
Archimedes' Box: Diagonal Therapeutics Raises $128 Million to Discover Agonist Antibodies
By Jonathan D. Grinstein, PhD, GEN Edge, April 3, 2024.
Hosted on Acast. See acast.com/privacy for more information.
View all episodes
By Genetic Engineering & Biotechnology News (GEN)
5
44 ratings
Episode 16 (April 5, 2024): This week, the GEN editors discussed deep proteome profiling of home-sampled dried blood spots to assess the effects of SARS-CoV-2 in mildly symptomatic or asymptomatic, rapid liquid nitrogen treatment for converting tumor cells into carriers for gene editing tools that target cancer in vivo, Verve Therapeutics’ pausing of a clinical trial due to a serious adverse event, Iambic Therapeutics’ advancement of its first AI-designed candidate into the clinic, and the launch of Diagonal Therapeutics to find agonist antibodies for heteromeric receptor complexes.
Featuring Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN), Jonathan Grinstein, PhD, (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM)
Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:
The State of Omics 2024 Registration
GEN Summit
COVID-19 Infections Detected in Dried Blood Spots via At-Home Proteomic Profiling
By GEN, April 2, 2024.
CRISPR-Cas9 Targets Lung Cancer Using Cryo-Shocked Tumor Cells
By GEN, March 31, 2024.
Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers
By Alex Philipidis, GEN, April 3, 2024.
Archimedes' Box: Diagonal Therapeutics Raises $128 Million to Discover Agonist Antibodies
By Jonathan D. Grinstein, PhD, GEN Edge, April 3, 2024.
Hosted on Acast. See acast.com/privacy for more information.
More shows like Touching Base
View all
Living on Earth
464 Listeners
On the Media
9,176 Listeners
Nature Podcast
759 Listeners
Science Magazine Podcast
813 Listeners
Economist Podcasts
4,219 Listeners
Fareed Zakaria GPS
3,393 Listeners
The Daily
110,877 Listeners
KFF Health News' 'What the Health?'
478 Listeners
The Readout Loud
316 Listeners
Sean Carroll's Mindscape: Science, Society, Philosophy, Culture, Arts, and Ideas
4,114 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
30 Listeners
The Ezra Klein Show
15,529 Listeners
Biotech Hangout
18 Listeners
The Opinions
469 Listeners